VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.
Trends Mol Med. 2007;13(6):223-30 - PMID: 17462954 - PMCID: PMC2686126 - DOI: 10.1016/j.molmed.2007.04.001
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer.
Nat Clin Pract Oncol. 2007;4(5):316-21 - PMID: 17464339 - PMCID: PMC2686127 - DOI: 10.1038/ncponc0813
Anti-VEGFR-3 therapy and lymph node metastasis [corrected].
Cancer Res. 2007;67(10):5055; author reply 5056 - PMID: 17510438 - DOI: 10.1158/0008-5472.CAN-06-2935
Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors.
Cancer Res. 2007;67(11):5076-82 - PMID: 17545583 - DOI: 10.1158/0008-5472.CAN-06-3664
Modeling the flow of dense suspensions of deformable particles in three dimensions.
Phys Rev E Stat Nonlin Soft Matter Phys. 2007;75(6 Pt 2):066707 - PMID: 17677389 - PMCID: PMC2752716 - DOI: 10.1103/PhysRevE.75.066707
Down-regulation of placenta growth factor by promoter hypermethylation in human lung and colon carcinoma.
Mol Cancer Res. 2007;5(9):873-80 - PMID: 17704140 - DOI: 10.1158/1541-7786.MCR-06-0141
Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers.
J Clin Oncol. 2007;25(26):4033-42 - PMID: 17827451 - PMCID: PMC2686120 - DOI: 10.1200/JCO.2007.11.3985
Non-uniform plasma leakage affects local hematocrit and blood flow: implications for inflammation and tumor perfusion.
Ann Biomed Eng. 2007;35(12):2121-9 - PMID: 17846892 - PMCID: PMC2752713 - DOI: 10.1007/s10439-007-9377-8
Targeted therapy in rectal cancer.
Oncology (Williston Park). 2007;21(9):1055-65; discussion 1065, 1070, 1075 passim - PMID: 17910311 - PMCID: PMC2686129
alphaPlGF: a new kid on the antiangiogenesis block.
Cell. 2007;131(3):443-5 - PMID: 17981110 - DOI: 10.1016/j.cell.2007.10.023
Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels.
Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus.
Cancer Res. 2007;67(22):10664-8 - PMID: 18006807 - DOI: 10.1158/0008-5472.CAN-07-3107
Antiangiogenic agents for the treatment of glioblastoma.
Expert Opin Investig Drugs. 2007;16(12):1895-908 - PMID: 18041999 - DOI: 10.1517/13543784.16.12.1895
Differential gene expression of primary cultured lymphatic and blood vascular endothelial cells.
Small blood vessel engineering.
Methods Mol Med. 2007;140:183-95 - PMID: 18085210 - DOI: 10.1007/978-1-59745-443-8_11
Blood cell interactions and segregation in flow.
Ann Biomed Eng. 2008;36(4):534-44 - PMID: 18188702 - PMCID: PMC2752714 - DOI: 10.1007/s10439-007-9429-0
Taming vessels to treat cancer.
Sci Am. 2008;298(1):56-63 - PMID: 18225696 - DOI: 10.1038/scientificamerican0108-56
Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature.
Perivascular nitric oxide gradients normalize tumor vasculature.
Nat Med. 2008;14(3):255-7 - PMID: 18278052 - DOI: 10.1038/nm1730
A protocol for a lung neovascularization model in rodents.
A protocol for phenotypic detection and characterization of vascular cells of different origins in a lung neovascularization model in rodents.
Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer.
Nat Rev Cancer. 2008;8(4):309-16 - PMID: 18337733 - DOI: 10.1038/nrc2346
Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors.
Cancer Res. 2008;68(10):3795-802 - PMID: 18483263 - PMCID: PMC2871708 - DOI: 10.1158/0008-5472.CAN-07-6193
Histopathologic findings and establishment of novel tumor lines from spontaneous tumors in FVB/N mice.
Comp Med. 2008;58(3):253-63 - PMID: 18589867 - PMCID: PMC2693079
Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib.
Mol Cancer Ther. 2008;7(8):2272-9 - PMID: 18687659 - PMCID: PMC2664998 - DOI: 10.1158/1535-7163.MCT-08-0182
VEGFR3: a new target for antiangiogenesis therapy?
Response criteria for glioma.
Nat Clin Pract Oncol. 2008;5(11):634-44 - PMID: 18711427 - PMCID: PMC4795821 - DOI: 10.1038/ncponc1204
Imaging angiogenesis and the microenvironment.
APMIS. 2008;116(7-8):695-715 - PMID: 18834413 - PMCID: PMC2859845 - DOI: 10.1111/j.1600-0463.2008.01148.x
Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas.
Curr Opin Neurol. 2008;21(6):728-35 - PMID: 18989120 - DOI: 10.1097/WCO.0b013e328318402a
A mathematical model of murine metabolic regulation by leptin: energy balance and defense of a stable body weight.
In vivo imaging of extracellular matrix remodeling by tumor-associated fibroblasts.
Mathematical modeling of herpes simplex virus distribution in solid tumors: implications for cancer gene therapy.
Clin Cancer Res. 2009;15(7):2352-60 - PMID: 19318482 - PMCID: PMC2872130 - DOI: 10.1158/1078-0432.CCR-08-2082
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.
Nat Rev Clin Oncol. 2009;6(4):229-36 - PMID: 19333229 - PMCID: PMC4793889 - DOI: 10.1038/nrclinonc.2009.14
Lattice Boltzmann simulation of blood flow in digitized vessel networks.
Comput Math Appl. 2008;55(7):1594-1600 - PMID: 19343080 - PMCID: PMC2390865 - DOI: 10.1016/j.camwa.2007.08.019
VEGFR2+PDGFRbeta+ circulating precursor cells participate in capillary restoration after hyperoxia acute lung injury (HALI).
J Cell Mol Med. 2009;13(9B):3720-9 - PMID: 19426150 - PMCID: PMC2832073 - DOI: 10.1111/j.1582-4934.2009.00785.x
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
J Clin Oncol. 2009;27(18):3027-35 - PMID: 19470923 - PMCID: PMC2702235 - DOI: 10.1200/JCO.2008.20.9908
Paradoxical effects of PDGF-BB overexpression in endothelial cells on engineered blood vessels in vivo.
Am J Pathol. 2009;175(1):294-302 - PMID: 19477947 - PMCID: PMC2708815 - DOI: 10.2353/ajpath.2009.080887
Angiogenesis as a therapeutic target in malignant gliomas.
Oncologist. 2009;14(6):621-36 - PMID: 19487335 - PMCID: PMC4790121 - DOI: 10.1634/theoncologist.2008-0272
Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.
Transport of macromolecules in tumor microcirculation.
Biotechnol Prog. 1985;1(2):81-94 - PMID: 20568145 - DOI: 10.1002/btpr.5420010205
Determinants of leukocyte margination in rectangular microchannels.
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
Multiscale measurements distinguish cellular and interstitial hindrances to diffusion in vivo.
Feasibility of in vivo imaging of fluorescent proteins using lifetime contrast.
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.
Cancer Res. 2009;69(13):5296-300 - PMID: 19549889 - PMCID: PMC2824172 - DOI: 10.1158/0008-5472.CAN-09-0814
Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials.
Int J Radiat Oncol Biol Phys. 2009;74(5):1580-91 - PMID: 19540073 - DOI: 10.1016/j.ijrobp.2009.03.047
A new target for tumor therapy.
N Engl J Med. 2009;360(25):2669-71 - PMID: 19535806 - PMCID: PMC4792114 - DOI: 10.1056/NEJMcibr0902054
Biomarkers of response and resistance to antiangiogenic therapy.
Nat Rev Clin Oncol. 2009;6(6):327-38 - PMID: 19483739 - PMCID: PMC3057433 - DOI: 10.1038/nrclinonc.2009.63
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.
J Clin Oncol. 2009;27(18):3020-6 - PMID: 19470921 - PMCID: PMC2702234 - DOI: 10.1200/JCO.2008.21.1771
PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment.
606